The potential prognostic and therapeutic application of tissue and circulating microRNAs in cervical cancer

DOI Web Site Web Site Web Site 1 Citations
  • Malihe Hasanzadeh
    Department of Gynecology Oncology Woman Health Research Center, Faculty of Medicine, Mashhad University of Medical Sciences Mashhad Iran
  • Mehraneh Movahedi
    Mashhad University of Medical Sciences Mashhad Iran
  • Marzieh Rejali
    Mashhad University of Medical Sciences Mashhad Iran
  • Faezeh Maleki
    Mashhad University of Medical Sciences Mashhad Iran
  • Mehrdad Moetamani‐Ahmadi
    Metabolic Syndrome Research Center Mashhad University of Medical Sciences Mashhad Iran
  • Sima Seifi
    Metabolic Syndrome Research Center Mashhad University of Medical Sciences Mashhad Iran
  • Zeinab Hosseini
    Mashhad University of Medical Sciences Mashhad Iran
  • Majid Khazaei
    Metabolic Syndrome Research Center Mashhad University of Medical Sciences Mashhad Iran
  • Forouzan Amerizadeh
    Metabolic Syndrome Research Center Mashhad University of Medical Sciences Mashhad Iran
  • Gordon A. Ferns
    Division of Medical Education Brighton & Sussex Medical School Brighton Sussex UK
  • Majid Rezayi
    Metabolic Syndrome Research Center Mashhad University of Medical Sciences Mashhad Iran
  • Amir Avan
    Metabolic Syndrome Research Center Mashhad University of Medical Sciences Mashhad Iran

Description

<jats:title>Abstract</jats:title><jats:p>Cervical cancer (CC) is a common malignancy in women and a major cause of cancer‐related mortality globally. Some novel biomarkers may enable the early diagnosis and monitoring of CC. MicroRNAs (miRNAs) are small noncoding RNAs that control gene translation at a posttranscriptional level. Hence the deregulation of these molecules can cause many diseases. There appears to be an association between aberrant miRNA expression and CC, but the molecular mechanisms involved in the development of CC remain unknown. The upregulation of some circulating miRNAs, for example, miRNA‐20a, miRNA‐203, miRNA‐21, miRNA‐205, miRNA‐218, and miR‐485‐5, as well as tissue‐specific miRNAs, for example, miR‐7, miR‐10a, miR‐17‐5p, miR‐135b, miR‐149, and miR‐203 have been found in patients with CC. There is also growing evidence for the importance of miRNAs in the development of drug resistance. This review therefore highlights recently published preclinical and clinical investigation performed on tissue specific and circulating miRNAs, as potential biomarkers for the detection of patients at early stages of CC, in the prediction of prognosis, and monitoring of their response to therapy.</jats:p>

Journal

Citations (1)*help

See more

Report a problem

Back to top